Viewing Study NCT06578559


Ignite Creation Date: 2025-12-24 @ 2:46 PM
Ignite Modification Date: 2026-01-25 @ 10:26 PM
Study NCT ID: NCT06578559
Status: RECRUITING
Last Update Posted: 2025-04-18
First Post: 2024-07-29
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
Sponsor: Gruppo Oncologico del Nord-Ovest
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module